인슐린 투여 기기 : 시장 인사이트, 경쟁 구도, 시장 예측(-2032년)

Insulin Delivery Devices Market Summary

• The global insulin delivery devices market is expected to increase from USD 35,587.79 million in 2024 to USD 52,983.06 million by 2032, reflecting strong and sustained growth.
• The global insulin delivery devices market is growing at a CAGR of 5.17% during the forecast period from 2025 to 2032.
• The market of insulin delivery devices is being primarily driven by the rising prevalence of diabetes, rising preference for home-based diabetes management, increasing awareness and patient education, increasing technological advancement in product design, and an increase in product development activities among the key market players.
• The leading companies operating in the insulin delivery devices market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo Corporation, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.
• North America is expected to dominate the insulin delivery devices market due to the high prevalence of diabetes, advanced healthcare infrastructure, and strong adoption of innovative technologies such as smart insulin pens, patch pumps, and automated insulin delivery systems. Widespread patient awareness, favorable reimbursement policies, and well-established distribution channels further support market growth in the region. Additionally, ongoing research and development by key players and the integration of digital health solutions enhance the demand for advanced insulin delivery devices across North America.
• In the product type segment of the insulin delivery devices market, the insulin pens category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Insulin Delivery Devices Market

• The rising prevalence of diabetes is leading to a surge in insulin delivery devices: The rising prevalence of diabetes worldwide is driving a surge in demand for insulin delivery devices. As more patients require regular and precise insulin administration, the need for user-friendly, efficient, and technologically advanced devices such as insulin pens, pumps, and patch systems has increased significantly, fuelling market growth.
• Rising preference for home-based diabetes management is escalating the market of insulin delivery devices: The growing preference for home-based diabetes management is boosting the insulin delivery devices market, as patients increasingly adopt convenient and easy-to-use solutions like insulin pens, patch pumps, and smart devices that allow self-administration and remote monitoring.
• Increasing awareness and patient education: Increasing awareness and patient education are driving the insulin delivery devices market, as well-informed patients are more likely to adopt advanced insulin pens, pumps, and smart delivery systems for effective diabetes management.
• Increasing technological advancements: Increasing technological advancements are boosting the insulin delivery devices market by introducing smart, connected, and automated systems that improve dosing accuracy, patient convenience, and overall diabetes management.

Insulin Delivery Devices Market Report Segmentation

This insulin delivery devices market report offers a comprehensive overview of the global insulin delivery devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Insulin Syringes, Insulin Pens [Reusable Insulin Pens and Disposable Insulin Pens], Insulin Pumps [Tethered/External Pumps and Patch Pumps], Insulin Injectors, and Others), End-User (Homecare Settings, Diabetes Centers, Hospitals, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing insulin delivery devices market.

Insulin delivery devices are medical tools used by people with diabetes to administer insulin, a hormone that helps regulate blood sugar levels. Since insulin cannot be taken orally, these devices provide a way to inject or deliver it into the body, typically into the subcutaneous (fatty) tissue.

These devices have evolved significantly over the years, moving from simple syringes to more advanced and automated systems. The choice of device depends on a person's specific insulin regimen, lifestyle, dexterity, vision, and personal preference.

The overall insulin delivery devices market is being boosted by a combination of factors, including the rising prevalence of diabetes, growing preference for home-based management, increased patient awareness and education, ongoing technological advancements in device design, and active product development by key market players. Together, these factors are driving higher adoption of innovative, convenient, and efficient insulin delivery solutions worldwide.

What are the latest Insulin Delivery Devices Market Dynamics and Trends?

The global market for insulin delivery devices is experiencing significant growth, driven by a confluence of rising diabetes prevalence and the increasing adoption of home-based diabetes management.

The escalating number of people diagnosed with diabetes is the primary driver of market expansion. According to recent data, approximately 591 million people worldwide were living with diabetes in 2025. Projections indicate this number could rise to around 854 million by 2050, representing a substantial 46% increase. With over 90% of these cases being Type 2 diabetes, a larger patient population requires effective and convenient solutions for regular insulin administration, fuelling demand for a diverse range of delivery devices.

Additionally, the shift from traditional hospital-based treatment to convenient home-based diabetes management is a major catalyst for market growth. Modern insulin delivery devices, such as insulin pens, patch pumps, and automated systems, empower patients to self-manage their condition safely and discreetly, reducing the need for frequent hospital visits. These devices improve patient adherence to treatment plans and facilitate remote monitoring by healthcare providers, driving a higher demand for innovative technologies. For example, in March 2024, the FDA cleared the Sequel Twist AID System, the first automated insulin delivery (AID) system to directly measure insulin delivery volume and flow, which enhances the rapid detection of blockages and other issues.

Technological advancements have also reshaped the industry, as the industry is experiencing a notable shift towards wearable and automated insulin delivery (AID) devices. Insulin pumps and patch pumps offer continuous insulin infusion, providing greater convenience and discretion for users. A key development in this space is the push for regulatory approvals. For instance, in January 2024, PharmaSens, a Swiss medical device company, submitted an FDA application for its 'niia essential' insulin patch pump system. This application, following its ISO 13485 certification in November 2023, is a significant step toward making advanced, patient-centric insulin pump technology more widely available.

However, the market's growth faces several challenges. The presence of effective oral medications for diabetes and an increased number of product recalls pose challenges. Additionally, high costs, limited reimbursement in certain regions, and a steep learning curve for advanced technologies may limit adoption, particularly among older patients or those in developing economies. The lack of interoperability between devices and patient apprehension towards needles also present persistent hurdles that the industry must address.

Insulin Delivery Devices Market Segment Analysis

Insulin Delivery Devices Market by Product Type (Insulin Syringes, Insulin Pens [Reusable Insulin Pens and Disposable Insulin Pens], Insulin Pumps [Tethered/External Pumps and Patch Pumps], Insulin Injectors, and Others), End-User (Homecare Settings, Diabetes Centers, Hospitals, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Product Type: Insulin Pens Category Dominates the Market

The insulin pens segment holds a dominant position in the insulin delivery devices market, capturing a substantial 45% share in 2024. This leadership is primarily attributed to the widespread adoption of reusable insulin pens, which are projected to hold the largest market share within this segment. Reusable pens are gaining popularity for a variety of compelling reasons. They offer significant cost-effectiveness and are more environmentally friendly, as they allow patients to replace insulin cartridges without discarding the entire device. Beyond these benefits, they provide enhanced dosing accuracy, improved ease of use, and customizable features, all of which contribute to better adherence to insulin therapy.

The rise of reusable pens also reflects a broader shift towards more advanced and connected diabetes management. Recent advancements in their design, such as improved ergonomics, integrated memory functions to track dose history, and seamless integration with digital health platforms, have made them increasingly appealing to tech-savvy patients and healthcare providers.

This trend is particularly strong in developed regions with advanced healthcare infrastructure and higher disposable incomes, where patients value long-term usability and sustainability. For example, in May 2025, GO-Pen ApS received FDA 510(k) clearance for the GO-PEN(R), a user-filled pen that is compatible with standard insulin vials. This innovation provides a more affordable and sustainable alternative to traditional pens, demonstrating how the industry is evolving to address both cost and environmental concerns. The continued development and approval of such devices are expected to further boost the market for reusable insulin pens, thereby strengthening the overall insulin delivery devices market.

By End-User: Homecare Settings Dominates the Market

Home care settings are playing a crucial role in boosting the insulin delivery devices market by enabling patients to manage diabetes more independently and effectively in the comfort of their homes. With devices such as reusable insulin pens, insulin pumps, and smart delivery systems, patients can achieve accurate dosing, maintain better glycemic control, and reduce reliance on frequent hospital visits. This shift toward home-based care improves convenience, lowers healthcare costs, and supports patient adherence to long-term therapy. Moreover, the integration of digital health tools and remote monitoring in home care settings further enhances disease management, driving higher demand for advanced insulin delivery devices.

Insulin Delivery Devices Market Regional Analysis

North America Insulin Delivery Devices Market Trends

North America is the dominant force in the global insulin delivery devices market, holding a substantial 36% market share in 2024. This leadership position is driven by a combination of a high burden of diabetes, a robust healthcare infrastructure, and a strong culture of adopting innovative medical technologies.

The foundation of this market dominance is the significant prevalence of diabetes in the region. According to the Centers for Disease Prevention and Control (CDC), over 38.4 million people, or 11.6% of the U.S. population, were living with diabetes in 2024. This massive patient pool requires daily insulin therapy, making advanced devices like smart insulin pens, patch pumps, and automated insulin delivery (AID) systems essential for disease management. The U.S. also leads in healthcare expenditure, which, combined with favorable reimbursement policies, allows for greater access to these sophisticated and often costly devices.

Beyond prevalence, several interconnected factors contribute to the region's market leadership. The mature healthcare infrastructure facilitates the seamless integration of new devices into clinical practice. Additionally, proactive diabetes awareness programs play a crucial role. Initiatives from organizations like the CDC educate both patients and healthcare providers on the benefits of proactive care and the latest technological advancements. This not only promotes early diagnosis but also drives the adoption of advanced devices, as patients become more informed about their options for self-management.

Finally, a highly competitive landscape, marked by continuous research and development, further solidifies North America's position. The presence of numerous key market players actively involved in product development, strategic partnerships, and mergers and acquisitions fuels innovation. For example, Embecta Corp.'s submission of a 510(k) premarket application for a new disposable insulin delivery system and Beta Bionics' FDA approval for its iLet ACE Insulin Pump in 2023 illustrate the ongoing commitment to bringing next-generation devices to market. This dynamic environment ensures a steady stream of cutting-edge products, reinforcing the region's market dominance during the forecast period.

Europe Insulin Delivery Devices Market Trends

Europe is a significant driver of the insulin delivery devices market, fueled by its robust healthcare infrastructure, rising diabetes prevalence, and a strong preference for advanced, connected technologies. The region faces a growing diabetes epidemic; according to the International Diabetes Federation, approximately 59.8 million people in Europe were living with diabetes in 2024, with that number projected to increase to 72.4 million by 2050. This demographic shift has created a pressing need for effective and accessible diabetes management tools. In response, European countries are actively promoting early diagnosis and proactive care through awareness campaigns and favorable reimbursement policies, which have encouraged the adoption of innovative solutions like reusable pens, insulin pumps, and smart devices.

Furthermore, patient and provider preferences for eco-friendly, cost-effective, and technologically advanced options are fueling market expansion. This is evident in the push for devices that offer greater connectivity and convenience. The integration of digital health platforms and telemedicine is a key trend, allowing for real-time data sharing between patients and healthcare providers. This not only improves treatment adherence but also enables remote monitoring and personalized care, which is particularly vital for chronic conditions like diabetes.

The European market is also a hub for innovation, with leading manufacturers continually launching new products and expanding the indications for existing ones. A prime example is Medtronic plc, which in July 2025 received CE Mark approval to expand the use of its MiniMed(TM) 780G system. This pivotal approval allows the automated insulin delivery (AID) system to be used by a much broader patient population, including individuals as young as two, pregnant women, and people with insulin-requiring Type 2 diabetes. This expansion, based on rigorous clinical data, highlights a commitment to making advanced technology available to a more diverse range of patients, thereby solidifying Europe's role as a key growth driver in the global insulin delivery devices market.

Asia-Pacific Insulin Delivery Devices Market Trends

The Asia-Pacific region is emerging as a key growth driver in the insulin delivery devices market, propelled by a rapidly escalating prevalence of diabetes. This surge is a direct result of urbanization, increasingly sedentary lifestyles, and evolving dietary habits across the region. Countries with vast populations, such as China and India, are at the forefront of this trend, creating a massive demand for effective and convenient insulin delivery solutions like pens, pumps, and smart devices. For example, recent studies in India estimated that 77 million people over the age of 18 were living with Type 2 diabetes, with an additional 25 million considered prediabetic. This significant patient pool makes advanced insulin delivery systems essential for managing the disease and improving patient outcomes.

Governments and healthcare organizations are proactively responding to this health crisis. They are actively investing in diabetes awareness campaigns, promoting early diagnosis, and improving access to treatment. These initiatives, combined with expanding healthcare infrastructure, are accelerating a fundamental shift from conventional insulin delivery methods to modern, user-friendly systems. Additionally, the increasing presence of global market players is strengthening the market's growth. These companies are establishing local partnerships and gaining regulatory approvals for their innovative products, ensuring a steady supply of cutting-edge technology. For instance, the collaboration between global and local firms is not only improving product availability but also adapting devices to regional needs, such as a greater focus on affordability and home-based care.

Furthermore, the growing adoption of digital health platforms and telemedicine is transforming diabetes care in the region. These technologies enhance patient adherence and convenience by enabling remote monitoring, real-time data analysis, and personalized treatment plans. Collectively, these factors, from the demographic shift and government support to technological innovation and strategic partnerships, position Asia-Pacific as one of the fastest-growing regions for insulin delivery devices, offering significant opportunities for market expansion.

Who are the major players in the insulin delivery devices market?

The following are the leading companies in the insulin delivery devices market. These companies collectively hold the largest market share and dictate industry trends.

• Becton, Dickinson and Company
• Medtronic
• Novo Nordisk A/S
• Ypsomed Holding AG
• Tandem Diabetes Care, Inc.
• Biocon Ltd.
• Eli Lilly and Company
• Insulet Corporation
• Abbott
• Terumo Corporation
• CeQur
• EOFLOW CO., LTD
• European Pharma Group BV
• Roche
• Sanofi
• Hindustan Syringes & Medical Devices Ltd.
• Ocean (Hangzhou) Medical Technology Co Ltd.
• Owen Mumford
• SOOIL Developments Co., Ltd.
• SUNGSHIM MEDICAL CO., LTD
• Others

How is the competitive landscape shaping the Insulin Delivery Devices market?

The insulin delivery devices market is mainly dominated by a few big companies like Medtronic, Insulet, Tandem, Novo Nordisk, Sanofi, Eli Lilly, Roche, and Ypsomed, which makes the market highly concentrated. These companies stay ahead by offering advanced technologies such as automated insulin systems, tubeless pumps, and smart reusable pens, along with digital platforms that connect devices to apps and cloud systems. Smaller players and startups are also entering the market with affordable or specialized products, especially in price-sensitive regions, which adds some competition. However, the big players hold the most influence because of their strong research, global presence, and ability to secure regulatory approvals and insurance coverage. Overall, competition is moving beyond just devices to offering complete diabetes care solutions, including digital health and remote monitoring.

Recent Developmental Activities in the Insulin Delivery Devices Market

• In July 2025, Medtronic plc. announced that it had received CE Mark in Europe to expand indications of the MiniMed(TM) 780G system for individuals aged 2 years and older, during pregnancy, and for those with type 2 insulin-requiring diabetes.
• In May 2025, GO-Pen ApS received FDA 510(k) clearance for the GO-PEN(R), a user-filled insulin pen compatible with standard insulin vials, providing an affordable alternative to traditional disposable pens.
• In April 2025, Dexcom received FDA clearance for the G7 15-Day sensor, which boasts extended wear time and enhanced accuracy for diabetes management.
• In August 2024, Medtronic plc., a global leader in healthcare technology, announced that the U.S. FDA had approved its Simplera(TM) continuous glucose monitor (CGM), the company's first disposable, all-in-one CGM. The device was half the size of previous Medtronic CGMs, with a discreet design that simplified insertion and wear, eliminating the need for overtape.
• In April 2024, Omnipod 5 by Insulet was approved by Health Canada. Omnipod 5 is an automated insulin delivery system.
• In February 2024, Insulet Corporation announced that it had received CE Mark approval under the European Medical Device Regulation for compatibility of the Abbott FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes.
• In February 2024, Tandem's Mobi pump, a tubeless insulin delivery device, was launched by Tandem Diabetes Care.

Insulin Delivery Devices Market Segmentation

• Insulin Delivery Devices by Product Type Exposure
• Insulin Syringes
• Insulin Pens
• Reusable Insulin Pens
• Disposable Insulin Pens
• Insulin Pumps
• Tethered/External Pumps
• Patch Pumps
• Insulin Injectors
• Others
• Insulin Delivery Devices End-Users Exposure
• Homecare Settings
• Diabetes Centers
• Hospitals
• Others
• Insulin Delivery Devices Geography Exposure
• North America Insulin Delivery Devices Market
• United States Insulin Delivery Devices Market
• Canada Insulin Delivery Devices Market
• Mexico Insulin Delivery Devices Market
• Europe Insulin Delivery Devices Market
• United Kingdom Insulin Delivery Devices Market
• Germany Insulin Delivery Devices Market
• France Insulin Delivery Devices Market
• Italy Insulin Delivery Devices Market
• Spain Insulin Delivery Devices Market
• Rest of Europe Insulin Delivery Devices Market
• Asia-Pacific Insulin Delivery Devices Market
• China Insulin Delivery Devices Market
• Japan Insulin Delivery Devices Market
• India Insulin Delivery Devices Market
• Australia Insulin Delivery Devices Market
• South Korea Insulin Delivery Devices Market
• Rest of Asia-Pacific Insulin Delivery Devices Market
• Rest of the World Insulin Delivery Devices Market
• South America Insulin Delivery Devices Market
• Middle East Insulin Delivery Devices Market
• Africa Insulin Delivery Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

Artificial Intelligence (AI) is transforming insulin delivery devices by enhancing precision, adaptability, and user convenience. Advanced AI-powered systems, such as Medtronic's MiniMed(TM) 780G, automatically adjust insulin delivery in real time based on continuous glucose monitoring (CGM) data, helping maintain blood glucose within target ranges and reducing the need for manual intervention. Other innovations include neural network-based systems that detect meals and recommend insulin doses to improve postprandial glucose control, and fully automated devices like Beta Bionics' iLet Bionic Pancreas, which learns individual insulin needs without requiring carb counting or manual corrections. AI-driven digital twin technologies, such as GlyTwin, simulate a patient's glucose response to lifestyle and dietary factors, providing personalized recommendations for optimal insulin therapy. In inpatient settings, systems like Glucommander use AI to automate intravenous insulin dosing, improving efficiency and reducing human error. Collectively, these AI-powered applications are making insulin delivery more personalized, efficient, and effective, and ongoing advancements are expected to further enhance patient outcomes and ease of diabetes management.

U.S. Tariff Impact Analysis on Insulin Delivery Devices Market:

The recent U.S. tariffs on medical devices, including insulin delivery systems, have introduced several challenges for both manufacturers and patients. These tariffs, which affect a significant portion of medical devices, have led to increased production costs for companies that rely on imported components. Manufacturers are responding by exploring strategies to mitigate these costs, such as optimizing supply chains and adjusting manufacturing operations. However, these adjustments may not fully offset the increased expenses, potentially leading to higher prices for consumers. This price increase could result in reduced access to essential diabetes management tools for patients, particularly those without comprehensive insurance coverage. Physicians have expressed concern that these tariffs may exacerbate existing affordability issues, leading some patients to delay or forgo necessary treatments. In summary, the U.S. tariffs on medical devices are contributing to increased production costs, which may translate into higher prices for insulin delivery systems. This situation poses a risk to patient access and adherence to diabetes management regimens, highlighting the need for careful consideration of trade policies in the healthcare sector.

How This Analysis Helps Clients

• Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
• Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
• Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
• Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the insulin delivery devices market report study

• Market size analysis for the current insulin delivery devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the insulin delivery devices market.
• Various opportunities available for the other competitors in the insulin delivery devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current insulin delivery devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the insulin delivery devices market growth in the future?

Frequently Asked Questions for the Insulin Delivery Devices Market

1. What is the growth rate of the insulin delivery devices market?

• The insulin delivery devices market is estimated to grow at a CAGR of 5.17% during the forecast period from 2025 to 2032.

2. What is the market for insulin delivery devices?

• The insulin delivery devices market was valued at USD 35,587.79 million in 2024, and is expected to reach USD 52,983.06 million by 2032.

3. Which region has the highest share in the insulin delivery devices market?

• North America is expected to dominate the insulin delivery devices market due to the high prevalence of diabetes, advanced healthcare infrastructure, and strong adoption of innovative technologies such as smart insulin pens, patch pumps, and automated insulin delivery systems. Widespread patient awareness, favourable reimbursement policies, and well-established distribution channels further support market growth in the region. Additionally, ongoing research and development by key players and the integration of digital health solutions enhance the demand for advanced insulin delivery devices across North America.

4. What are the drivers for the insulin delivery devices market?

• The overall insulin delivery devices market is being boosted by a combination of factors, including the rising prevalence of diabetes, growing preference for home-based management, increased patient awareness and education, ongoing technological advancements in device design, and active product development by key market players. Together, these factors are driving higher adoption of innovative, convenient, and efficient insulin delivery solutions worldwide.

5. Who are the key players operating in the insulin delivery devices market?

• Some of the key market players operating in the insulin delivery devices market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

Table of Contents

1. Insulin Delivery Devices Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Insulin Delivery Devices Market Executive Summary

• 2.1 Market at Glance

3. Insulin Delivery Devices Market Key Factors Analysis

• 3.1 Insulin Delivery Devices Market Drivers
  • 3.1.1 The rising prevalence of diabetes
  • 3.1.2 Rising preference for home-based diabetes management
  • 3.1.3 Increasing awareness and patient education
  • 3.1.4 Increase in technological advancement
• 3.2 Insulin Delivery Devices Market Restraints and Challenges
  • 3.2.1 Presence of oral medication
  • 3.2.2 Increased number of product recalls
• 3.3 Insulin Delivery Devices Market Opportunity
  • 3.3.1 The shift toward advanced closed-loop insulin delivery systems

4. Impact Analysis

• 4.1 AI-Powered Innovations and Applications
• 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Insulin Delivery Devices Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Insulin Delivery Devices Market Assessment

• 7.1 By Product Type
  • 7.1.1 Insulin Syringes
  • 7.1.2 Insulin Pens
    • 7.1.2.1 Reusable Insulin Pens
    • 7.1.2.2 Disposable Insulin Pens
  • 7.1.3 Insulin Pumps
    • 7.1.3.1 Tethered/External Pumps
    • 7.1.3.2 Patch Pumps
  • 7.1.4 Insulin Injectors
  • 7.1.5 Others
• 7.2 By End-Users
  • 7.2.1 Homecare Settings
  • 7.2.2 Diabetes Centers
  • 7.2.3 Hospitals
  • 7.2.4 Others
• 7.3 By Geography
  • 7.3.1 North America
    • 7.3.1.1 United States Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.1.2 Canada Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.1.3 Mexico Insulin Delivery Devices Market Size in USD million (2022-2032)
  • 7.3.2 Europe
    • 7.3.2.1 France Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.2.2 Germany Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.2.3 United Kingdom Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.2.4 Italy Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.2.5 Spain Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.2.6 Rest of Europe Insulin Delivery Devices Market Size in USD million (2022-2032)
  • 7.3.3 Asia-Pacific
    • 7.3.3.1 China Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.3.2 Japan Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.3.3 India Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.3.4 Australia Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.3.5 South Korea Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.3.6 Rest of Asia-Pacific Insulin Delivery Devices Market Size in USD million (2022-2032)
  • 7.3.4 Rest of the World (RoW)
    • 7.3.4.1 Middle East Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.4.2 Africa Insulin Delivery Devices Market Size in USD million (2022-2032)
    • 7.3.4.3 South America Insulin Delivery Devices Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Insulin Delivery Devices Market Company and Product Profiles

• 10.1 Becton, Dickinson and Company
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 Medtronic
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 Novo Nordisk A/S
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Ypsomed Holding AG
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 Tandem Diabetes Care, Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 Biocon Ltd.
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 Eli Lilly and Company
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Insulet Corporation
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 Abbott
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 Terumo Corporation
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 CeQur
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 EOFLOW CO., LTD
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 European Pharma Group BV
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entropy
• 10.14 Roche
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entropy
• 10.15 Sanofi
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entropy
• 10.16 Hindustan Syringes & Medical Devices Ltd.
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entropy
• 10.17 Ocean (Hangzhou) Medical Technology Co Ltd.
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entropy
• 10.18 Owen Mumford
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entropy
• 10.19 SOOIL Developments Co., Ltd.
  • 10.19.1 Company Overview
  • 10.19.2 Company Snapshot
  • 10.19.3 Financial Overview
  • 10.19.4 Product Listing
  • 10.19.5 Entropy
• 10.20 SUNGSHIM MEDICAL CO., LTD
  • 10.20.1 Company Overview
  • 10.20.2 Company Snapshot
  • 10.20.3 Financial Overview
  • 10.20.4 Product Listing
  • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us